BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1792 related articles for article (PubMed ID: 26341640)

  • 1. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
    Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
    Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy.
    Luen SJ; Salgado R; Dieci MV; Vingiani A; Curigliano G; Gould RE; Castaneda C; D'Alfonso T; Sanchez J; Cheng E; Andreopoulou E; Castillo M; Adams S; Demaria S; Symmans WF; Michiels S; Loi S
    Ann Oncol; 2019 Feb; 30(2):236-242. PubMed ID: 30590484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy.
    Miyashita M; Sasano H; Tamaki K; Chan M; Hirakawa H; Suzuki A; Tada H; Watanabe G; Nemoto N; Nakagawa S; Ishida T; Ohuchi N
    Breast Cancer Res Treat; 2014 Dec; 148(3):525-34. PubMed ID: 25395319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of tumor-infiltrating lymphocytes for response to neoadjuvant chemotherapy and breast cancer prognosis.
    Li X; Tan Q; Li H; Yang X
    J Surg Oncol; 2021 Jan; 123(1):89-95. PubMed ID: 33047336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
    Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
    Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.
    Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Hatano T; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2018 Apr; 38(4):2311-2321. PubMed ID: 29599354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer.
    Hida AI; Watanabe T; Sagara Y; Kashiwaba M; Sagara Y; Aogi K; Ohi Y; Tanimoto A
    Breast Cancer Res Treat; 2019 Nov; 178(2):283-294. PubMed ID: 31402409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer.
    Asano Y; Kashiwagi S; Goto W; Kurata K; Noda S; Takashima T; Onoda N; Tanaka S; Ohsawa M; Hirakawa K
    Br J Surg; 2016 Jun; 103(7):845-54. PubMed ID: 26953091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis.
    Gao G; Wang Z; Qu X; Zhang Z
    BMC Cancer; 2020 Mar; 20(1):179. PubMed ID: 32131780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy.
    Bai YG; Gao GX; Zhang H; Zhang S; Liu YH; Duan XN; Xu L
    Chin Med J (Engl); 2020 Mar; 133(5):552-560. PubMed ID: 32044815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy.
    Chen S; Wang RX; Liu Y; Yang WT; Shao ZM
    Int J Cancer; 2017 Mar; 140(6):1384-1395. PubMed ID: 27925176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor infiltrating lymphocytes and neutrophil-to-lymphocyte ratio in relation to pathological complete remission to neoadjuvant therapy and prognosis in triple negative breast cancer.
    Zhao M; Xing H; He J; Wang X; Liu Y
    Pathol Res Pract; 2023 Aug; 248():154687. PubMed ID: 37478522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study.
    Dieci MV; Criscitiello C; Goubar A; Viale G; Conte P; Guarneri V; Ficarra G; Mathieu MC; Delaloge S; Curigliano G; Andre F
    Ann Oncol; 2014 Mar; 25(3):611-618. PubMed ID: 24401929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy.
    Pinard C; Debled M; Ben Rejeb H; Velasco V; Tunon de Lara C; Hoppe S; Richard E; Brouste V; Bonnefoi H; MacGrogan G
    Breast Cancer Res Treat; 2020 Jan; 179(1):11-23. PubMed ID: 31529299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic relevance of tumor‑infiltrating lymphocytes in residual tumor tissue from patients with triple‑negative breast cancer following neoadjuvant chemotherapy: A systematic review and meta‑analysis.
    Cao B; Zhang Z; Wang C; Lv X
    Oncol Lett; 2023 Oct; 26(4):441. PubMed ID: 37664648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in Tumor-infiltrating Lymphocytes After Neoadjuvant Chemotherapy and Clinical Significance in Triple Negative Breast Cancer.
    Lee H; Lee M; Seo JH; Gong G; Lee HJ
    Anticancer Res; 2020 Apr; 40(4):1883-1890. PubMed ID: 32234876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-bet
    Mori H; Kubo M; Kai M; Yamada M; Kurata K; Kawaji H; Kaneshiro K; Osako T; Nishimura R; Arima N; Okido M; Kishimoto J; Oda Y; Nakamura M
    Breast Cancer Res Treat; 2019 Aug; 176(3):569-577. PubMed ID: 31069590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic implications of tumor-infiltrating FoxP3+ regulatory T cells and CD8+ cytotoxic T cells in microsatellite-unstable gastric cancers.
    Kim KJ; Lee KS; Cho HJ; Kim YH; Yang HK; Kim WH; Kang GH
    Hum Pathol; 2014 Feb; 45(2):285-93. PubMed ID: 24331841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis.
    Ibrahim EM; Al-Foheidi ME; Al-Mansour MM; Kazkaz GA
    Breast Cancer Res Treat; 2014 Dec; 148(3):467-76. PubMed ID: 25361613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 90.